
GlycoMimetics Inc (CBIO) Stock Forecast & Price Target
GlycoMimetics Inc (CBIO) Analyst Ratings
Bulls say
Crescent Biopharma is downgraded to Neutral amidst the competitive sacituzumab tirumotecan (sac-TMT) and pembrolizumab regimen, which showed a stronger efficacy profile compared to CR-001 in the key 1L NSCLC comparison. The lower risk of progression or death and higher response rate of sac-TMT make it a more compelling option than CR-001. Additionally, the immature survival data of CR-001 also weakens its premium positioning, leading to the decision to downgrade to Neutral.
Bears say
Crescent Biopharma is facing significant competition in the development of its pipeline products, particularly CR-001, which is targeting the same PD-1/VEGF pathway as other companies such as Akeso Biopharma and Summit Therapeutics. The recent data from Pfizer's ASCO update for its ITGB6-directed ADC in combination with pembrolizumab showed a strong response rate, indicating that Crescent's CR-003/SKB105 program may not offer a significant improvement over existing treatments. This, coupled with the lack of attributed value to their ADC programs, presents risks for Crescent, and their stock carries a negative outlook.
This aggregate rating is based on analysts' research of GlycoMimetics Inc and is not a guaranteed prediction by Public.com or investment advice.
GlycoMimetics Inc (CBIO) Analyst Forecast & Price Prediction
Start investing in GlycoMimetics Inc (CBIO)
Order type
Buy in
Order amount
Est. shares
0 shares